Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Terminated; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: KOS-862

Study type: Interventional

Funder types: Industry

Identifiers

NCT00104130

KOS-202/NO18401

Details and patient eligibility

About

The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

Full description

This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age.
• Metastatic disease.
• One previous treatment including docetaxel (Taxotere).
• At least 3 weeks since last surgery/radiation/chemotherapy
• ECOG Performance Status of 0, 1 or 2

Exclusion criteria

• Active brain metastases

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)